CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ESSA Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ESSA Pharma Inc
999 West Broadway, Suite 720
Phone: (778) 331-0962p:778 331-0962 VANCOUVER, BC  V5Z 1K5  Canada Ticker: EPIXEPIX
Business Summary
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20249/30/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Richard M.Glickman 65 10/1/2010 10/1/2010
President, Chief Executive Officer, Director David R.Parkinson 72 1/7/2016 6/24/2015
Chief Financial Officer David S.Wood 62 8/1/2014 8/1/2014
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Realm Therapeutics plc 78 Cannon Street London PA United Kingdom

Business Names
Business Name
EPI
EPIX
ESSA Pharmaceuticals Corp.(ESSA Texas)

General Information
Number of Employees: 50 (As of 9/30/2023)
Outstanding Shares: 44,388,551 (As of 9/30/2024)
Stock Exchange: NASD
Fax Number: (778) 331-0962


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024